- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00583830
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC)
August 1, 2013 updated by: Human Genome Sciences Inc.
A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
111
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 10117
- Charite - Campus Mitte, Universitätsmedizin Berlin, Abteilung Onkologie und Hämatologie
-
Berlin, Germany, 10117
- Universitätsmedizin Berlin, Centrum für Innere Medizin
-
Gauting, Germany, 82131
- Asklepios Fachkliniken München-Gauting
-
Großhansdorf, Germany, 22927
- Krankenhaus Großhansdorf
-
Halle, Germany, 06120
- Krankenhaus Martha-Maria Halle-Dölau
-
Magdeburg, Germany, 39120
- Universitätsklinik Magdeburg, Klinik für Kardiologie, Angiologie und Pneumologie
-
Mainz, Germany, 55131
- Klinikum der Johannes-Gutenberg-Universität Mainz
-
Mannheim, Germany, 68167
- Universitätsklinikum Mannheim, Chirurgische Klinik
-
Oldenburg, Germany, 26121
- Pius-Hospital
-
Osnabrück, Germany, 49076
- Paracelsus Klinik, Zentrum für Tumordiagnostik und -therapie
-
-
-
-
-
Budapest, Hungary, 1145
- Fövárosi Önkormányzat uzsoki utcai Kórház
-
Budapest, Hungary, 1529
- Orszagos Koranyi Tbc es Pulmonologiai Intezet
-
Debrecen, Hungary, 4032
- Debrecen University, Medical and Health Center, Dept of Oncology
-
Debrecen, Hungary, 4043
- Kenézy Gyula Kórház, Debrecen, Pulmonológia
-
-
-
-
-
Bucuresti, Romania, 022328
- Institutul Oncologic 'Prof Dr. Al Trestioreanu' Bucuresti
-
Cluj-Napoca, Romania, 400015
- Institutul Oncologic 'Prof . Dr. I. Chiricuta' Cluj-Napoca
-
Oradea, Romania, 410032
- Spitalul Clinic Judetean Oradea, Oncology Department
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35213
- Birmingham Hematology and Oncology Associates, LLC
-
-
California
-
Rancho Mirage, California, United States, 92270
- Desert Hematology Oncology Medical Group, Inc.
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Health Sciences Center
-
-
Florida
-
Kissimmee, Florida, United States, 34741
- Osceola Cancer Center
-
West Palm Beach, Florida, United States, 33401
- Palm Beach Cancer Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
LaGrange, Illinois, United States, 60525
- LaGrange Oncology Associates
-
Skokie, Illinois, United States, 60076
- Orchard Research, LLC
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Kentuckiana Cancer Institute, PLLC
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland, Greenebaum Cancer Center
-
Chevy Chase, Maryland, United States, 20815
- Chevy Chase Health Care
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina: Hollings Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- The Sarah Cannon Cancer Center
-
-
Texas
-
San Antonio, Texas, United States, 78229
- UT Health Science Center at San Antonio, Be Well Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Fairfax-Northern Virginia Hematology Oncology, PC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with histologically or cytologically confirmed stage IIIB or stage IV advanced primary non-small cell lung cancinoma
- Age 18 years or older
Exclusion Criteria:
- Received investigational (not yet approved by a regulatory authority) or non-investigational agent to treat Lung Cancer
- Received radiation therapy within 4 weeks before randomization
- Major surgery within 4 weeks before randomization
- Minor surgery within 2 weeks before randomizaiton
- Systemic steroids within 1 week before randomization
- Any grade 2 or greater neuropathy
- History of severe (Grade 4) hypersensitivity reaction to products containing Cremophor EL (cyclosporine, teniposide)
- History of any infection requiring hospitalization or antibiotics within 2 weeks before randomization
- Known brain or spinal cord metastases
- History of other cancers within 5 years before randomization
- Known HIV, hepatitis-B or hepatitis-C infection
- Pregnant or breast-feeding women
- Previously treated with Mapatumumab
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: A
Paclitaxel and carboplatin
|
200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
Other Names:
AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Other Names:
|
EXPERIMENTAL: B
Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
|
200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
Other Names:
AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Other Names:
30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
|
EXPERIMENTAL: C
Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
|
200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
Other Names:
AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
Other Names:
30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response and Progression free survival
Time Frame: 6 cycles, or until disease progression or unacceptable toxicity develops
|
6 cycles, or until disease progression or unacceptable toxicity develops
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease control; Overall survival; Response duration and time to response in responders; Frequency and severity of treatment-emergent adverse events; Laboratory parameters; and Serum mapatumumab concentrations for use in a PK analysis.
Time Frame: 6 cycles, or until disease progression or unacceptable toxicity develops
|
6 cycles, or until disease progression or unacceptable toxicity develops
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (ACTUAL)
November 1, 2010
Study Completion (ACTUAL)
February 1, 2011
Study Registration Dates
First Submitted
December 20, 2007
First Submitted That Met QC Criteria
December 20, 2007
First Posted (ESTIMATE)
December 31, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
August 8, 2013
Last Update Submitted That Met QC Criteria
August 1, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Carboplatin
- Paclitaxel
- Antibodies, Monoclonal
- Mapatumumab
Other Study ID Numbers
- HGS1012-C1072
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on Paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium